The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) - Full Text View

Sponsor:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00043862

Purpose

This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy. Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.

Condition	Intervention	Phase
Small Cell Lung Cancer	Drug: topotecan	Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer

Drug Information available for: Topotecan hydrochloride Topotecan

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Response rate

Secondary Outcome Measures:

Time to Progression, response duration, survival, quantitative and qualitative assessment of tolerability

Enrollment:	60
Study Start Date:	August 2002

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or biopsy.
Women of reproductive potential must have a negative serum pregnancy test at the study screening visit.
Patients must give written informed consent to participate in the study.
Patients must be able to take oral medication.
Patients should be completely recovered from recent surgery.
Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
Patients must be evaluated by the radiation oncologist prior to study entry.

Exclusion Criteria:

Extensive Stage SCLC.
Women who are pregnant or lactating.
Use of an investigational drug within 30 days prior to the first dose of study medication.
Any medically/clinically significant active infection.
Symptoms of the SCLC spreading to the brain.
Patients with limited stage SCLC who have undergone complete resection with no measurable disease prior to starting chemotherapy.
Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk.
Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00043862

Hide Study Locations

Locations

United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85013 - 4496
United States, Arkansas
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
GSK Investigational Site
Los Angeles, California, United States, 90057
GSK Investigational Site
Fountain Valley, California, United States, 92708
GSK Investigational Site
Bakersfield, California, United States, 93309
United States, Florida
GSK Investigational Site
Gainesville, Florida, United States, 32610
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46260
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0098
United States, Louisiana
GSK Investigational Site
Shreveport, Louisiana, United States, 71103
GSK Investigational Site
New Orleans, Louisiana, United States, 70112
GSK Investigational Site
New Orleans, Louisiana, United States, 70121
United States, Maine
GSK Investigational Site
Scarborough, Maine, United States, 04074
United States, Massachusetts
GSK Investigational Site
Springfield, Massachusetts, United States, 01107
United States, Minnesota
GSK Investigational Site
Minneapolis, Minnesota, United States, 55455
GSK Investigational Site
Duluth, Minnesota, United States, 55805
GSK Investigational Site
Robbinsdale, Minnesota, United States, 55422
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63141
United States, Montana
GSK Investigational Site
St. Louis, Montana, United States, 63110
United States, New Mexico
GSK Investigational Site
Albuquerque, New Mexico, United States, 87109
United States, North Carolina
GSK Investigational Site
Raleigh, North Carolina, United States, 27609
United States, Ohio
GSK Investigational Site
Toledo, Ohio, United States, 43614-5809
GSK Investigational Site
Cincinnati, Ohio, United States, 45236
GSK Investigational Site
Akron, Ohio, United States, 44304
GSK Investigational Site
Cleveland, Ohio, United States, 44106
United States, Texas
GSK Investigational Site
Fort Worth, Texas, United States, 76104
GSK Investigational Site
San Antonio, Texas, United States, 78229
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53792
GSK Investigational Site
Wausau, Wisconsin, United States, 54401
GSK Investigational Site
Green Bay, Wisconsin, United States, 54301
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
GSK Investigational Site
La Crosse, Wisconsin, United States, 54601

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, MD

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	104864/535
Study First Received:	August 14, 2002
Last Updated:	May 15, 2009
ClinicalTrials.gov Identifier:	NCT00043862 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

Small Cell Lung Cancer
Radiation Sensitization
topotecan
Hycamtin

oral
limited stage
newly diagnosed

Additional relevant MeSH terms:

Thoracic Neoplasms
Carcinoma, Neuroendocrine
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Neoplasms, Nerve Tissue
Physiological Effects of Drugs
Neoplasms by Site
Respiratory Tract Diseases
Lung Neoplasms
Neoplasms, Germ Cell and Embryonal
Therapeutic Uses
Respiratory Tract Neoplasms
Neoplasms by Histologic Type

Enzyme Inhibitors
Pharmacologic Actions
Neuroendocrine Tumors
Carcinoma
Carcinoma, Small Cell
Neuroectodermal Tumors
Neoplasms
Radiation-Sensitizing Agents
Lung Diseases
Adenocarcinoma
Topotecan
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2009